Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ImmunoPrecise Antibodies Ltd.

< Previous 1 2 Next >
$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA Announces Closing of $1.265 Million Public Offering of Common Shares
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA Announces Pricing of $1.1 Million Public Offering of Common Shares
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
IPA Announces Proposed Public Offering of Common Shares
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Tickers IPA
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.